This recombinant monoclonal antibody is a research-grade biosimilar to Ebdarokimab, designed for research applications targeting IL12B (interleukin-12 subunit beta), also known as IL-12p40. IL12B encodes a crucial subunit shared by both IL-12 and IL-23, two pro-inflammatory cytokines that play pivotal roles in immune regulation and T-cell differentiation. IL-12 promotes Th1 cell development and IFN-γ production, while IL-23 supports Th17 cell maintenance and function. Dysregulation of IL12B-related pathways has been implicated in numerous autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, inflammatory bowel disease, and Crohn's disease, making it a significant target for immunological research.
Ebdarokimab is a therapeutic monoclonal antibody that specifically binds to the p40 subunit, thereby neutralizing both IL-12 and IL-23 signaling pathways. This biosimilar antibody provides researchers with a valuable tool for investigating IL12B-mediated immune responses, studying cytokine network dynamics, and exploring therapeutic mechanisms in inflammatory disease models. It supports diverse immunology research applications, including cytokine neutralization studies and pathway analysis experiments.
Email: support@cusabio.com
Distributors Worldwide